On 6 June 2016, the listed biopharmaceutical company Ablynx, focused on the discovery and development of Nanobodies® has successfully raised EUR 74.2 million through a private placement of new shares amongst institutional investors via an accelerated bookbuilding procedure, while an initial target of EUR 60 million was set. The shares have been offered for EUR 13.40 per share and have been admitted to trading on Euronext Brussels.

For this private placement, Ablynx was assisted by a Eubelius team led by Lars Van Bever, Erwin Destruyver and Robin Van Gysel.